Formulation and Chemopreventive Efficacy of Imatinib-Loaded Chitosan-Coated Nanoparticles in DEN-Induced Hepatocellular Carcinoma in Wistar Rats
Keywords:
Hepatocellular carcinoma; Imatinib; Chitosan-coated nanoparticles; Diethylnitrosamine; Chemoprevention; Nanoparticulate drug delivery.Abstract
Background and Objective: Hepatocellular Carcinoma (HCC) is one of the most lethal liver primary cancers, with a high mortality and morbidity rate. Tyrosine kinase inhibitors (imatinib) has been found to have potential anticancer activity against some solid tumors and provide therapeutic benefit, but may be limited by poor drug delivery and systemic toxicity. The use of chitosan coated nanoparticles as a novel drug delivery system provides great potential for enhancing drug uptake, cellular uptake and therapeutic efficacy. The objective of the present study was to develop and characterize imatinib loaded chitosan-coated nanoparticles and to explore the chemopreventive effect of IMT-CSNPs on the diethylnitrosamine (DEN)-induced hepatocellular carcinoma in rats of Wistar strain.
Methods: To prepare imatinib-loaded chitosan-coated nanoparticles, the ionic gelation method was used and the nanoparticles were characterized with regard to particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency, drug loading and in-vitro drug release. The in-vivo chemopreventive activity was evaluated in DEN induced HCC model in wistar rats. The animals were divided into normal control group, DEN-induced HCC normal control group, standard treatment group, and IMT-CSNP treated group. The efficacy of treatment was evaluated using serum liver function markers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, markers of oxidative stress, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and histopathological examination of liver tissue.
Results: The optimized IMT-CSNP formulation demonstrated a mean particle size of 185.6 ± 8.4 nm, PDI of 0.218 ± 0.032, and zeta potential of +32.4 ± 2.6 mV. The encapsulation efficiency and drug loading were found to be 86.7 ± 3.2% and 12.4 ± 1.1%, respectively. An in-vitro drug release study was performed, which exhibited about 78.5% cumulative drug release within 24 h. The serum levels of ALT, AST, ALP and MDA showed a significant increase in the DEN-induced HCC group when compared to the normal control. These biomarkers were significantly decreased after treatment with IMT-CSNPs with illustrative reduction of 48.6%, 45.2%, 42.8% and 51.3%, respectively, compared to the untreated HCC group. The histopathological examination showed that the Hepatic cellular degeneration, inflammatory infiltration and necrotic changes were reduced in the group of animals treated with nanoparticles.
Conclusion: Based on these results, imatinib-loaded chitosan-coated nanoparticles could prove to be a promising nanotechnology-based method in improving the chemopreventive effect of imatinib against DEN-induced HCC. The observed benefits on biochemical, oxidative stress and histopathological parameters suggest a need for further research to define the mechanisms of action, pharmacokinetics and safety of the therapeutic use.

